Targovax
133 articles about Targovax
-
Agenus and Targovax partner on a KRAS cancer vaccine, Elixirgen and Taisho target aging and Tonix and Mass General team up again to fight kidney transplant rejection.
-
Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™
3/7/2022
Agenus and Targovax today announce that they have entered into a clinical collaboration and supply agreement to combine Targovax’s TG mutant KRAS cancer vaccines.
-
Targovax ASA strengthens management with Lubor Gaal as Chief Financial Officer
2/28/2022
Targovax ASA a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, announces that it has appointed Dr. Lubor Gaal as Chief Financial Officer, effective as of 7 March 2022.
-
Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation Norway
1/12/2022
Targovax ASA announces that Innovation Norway has awarded Targovax an NOK 8.2m grant to accelerate product development activities related to the company's TG mutant RAS vaccine program and planned clinical trials.
-
Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesothelioma
12/20/2021
Targovax ASA, a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, announces mOS of 25.0 months for treatment with ONCOS-102 in combination with Standard of Care chemotherapy in malignant pleural mesothelioma in the subgroup of patients receiving therapy in the first-line setting.
-
Targovax ASA: Third quarter 2021 results
11/4/2021
Targovax ASA, a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces its third quarter 2021 results.
-
Targovax: Presentation material for today's webcast
10/25/2021
Targovax will at 14:00 CEST today host a live webcast presentation held by the company's newly appointed CEO Erik Digman Wiklund .
-
Targovax ASA appoints Dr. Erik Digman Wiklund as new CEO
10/20/2021
Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, announces the appointment of Dr. Erik Digman Wiklund as Chief Executive Officer.
-
Targovax to present at upcoming conferences
10/19/2021
Targovax ASA today announces that members of its executive management team are invited to present and participate in upcoming conferences. Økonomisk Ugebrev's Life Science Investor conference Date: 20 October 2021 Presenter: Lone Ottesen (CDO) Time: 14:35 CET
-
Targovax ASA: Two abstracts accepted at the SITC Congress
10/6/2021
Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, announces that two abstracts has been accepted for poster presentation at the Society for Immunotherapy of Cancer Annual Meeting.
-
Targovax ASA appoints Ola Melin as Head of Manufacturing
9/30/2021
Targovax ASA announces the appointment of Ola Melin as Head of Manufacturing. He will take a leading role in driving Targovax's Chemistry, Manufacturing, and Controls program forward.
-
Targovax granted European Patent for ONCOS-102 in combination with chemotherapy
9/24/2021
Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, announce that the European Patent Office has granted EU Patent no EP3402889.
-
Targovax ASA: Poster at European Society for Medical Oncology (ESMO)
9/16/2021
Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, announces that the poster "A pilot study of Engineered Adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma" is now available at the ESMO congress website and on the Company's website.
-
Targovax ASA: Abstract on ONCOS-102 phase 1 trial in advanced PD1 refractory melanoma is accepted at ESMO Congress
8/27/2021
Targovax ASA announces that the abstract "A pilot study of Engineered Adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma" will be presented as an e-poster at the European Society for Medical Oncology congress by Dr Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center.
-
Targovax ASA: second quarter and first half year 2021 results
8/18/2021
Targovax ASA, a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces its second quarter and first half year 2021 results.
-
Targovax to present at upcoming scientific conferences
8/16/2021
Targovax ASA, announces that members of its executive management team is invited to present and participate at upcoming conferences.
-
Targovax ASA: Invitation to presentation of Targovax's second quarter and first half 2021 results, Wednesday 18 August
8/9/2021
Targovax ASA will announce its second quarter and first half 2021 results on Wednesday 18 August 2021.
-
Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer
7/1/2021
Targovax ASA announces the appointment of Dr Lone Ottesen, MD, PhD as Chief Development Officer. She will take a leading role in driving the clinical programs forward.
-
Targovax to present at the 4th Annual Next Gen Immuno-oncology Virtual Congress-US Edition
6/28/2021
Targovax ASA, announces that Victor Levitsky, Chief Scientific Officer of Targovax, is invited to present at the 4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition.
-
Targovax receives Fast Track designation for ONCOS-102 in melanoma
6/22/2021
Targovax ASA, a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, announces that its lead clinical candidate ONCOS-102 has received Fast Track designation in PD-1-refractory advanced melanoma from the US FDA.